220 related articles for article (PubMed ID: 10832433)
1. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between response and survival].
Ohtsu A; Boku N; Miyata Y; Ohkuwa M
Gan To Kagaku Ryoho; 2000 May; 27(5):689-95. PubMed ID: 10832436
[TBL] [Abstract][Full Text] [Related]
3. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
Buyse M
Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
[TBL] [Abstract][Full Text] [Related]
4. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
5. [Surrogate endpoints].
Hill C
Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
[TBL] [Abstract][Full Text] [Related]
6. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
7. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
Piedbois P; Buyse M
Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
[TBL] [Abstract][Full Text] [Related]
8. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
Baker SG
Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
10. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
Baker SG
Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
[TBL] [Abstract][Full Text] [Related]
11. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
12. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
13. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
Piedbois P; Miller Croswell J
Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
[TBL] [Abstract][Full Text] [Related]
14. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-PĂ©lissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
15. Alternate endpoints for screening phase II studies.
Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
[TBL] [Abstract][Full Text] [Related]
16. [Validation of surrogate endpoints in digestive oncology].
Methy N; Bedenne L; Bonnetain F
Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
[TBL] [Abstract][Full Text] [Related]
17. Potential surrogate endpoints in cancer research--some considerations and examples.
Duffy SW; Treasure FP
Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
[TBL] [Abstract][Full Text] [Related]
18. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
Hughes MD
Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
[TBL] [Abstract][Full Text] [Related]
19. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues.
Chakravarty A; Sridhara R
Stat Methods Med Res; 2008 Oct; 17(5):515-8. PubMed ID: 18285437
[TBL] [Abstract][Full Text] [Related]
20. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
Lonn E
Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]